Clinical trial Recruiting at 1 site Interventional Ages 19 and up

Noninferiority test of a sirolimus-ascorbic acid stent vs everolimus stent in heart disease patients

Official title: Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers

Run by Asan Medical Center · NCT07566091 · Data updated 2026-11-12

This study tests whether a sirolimus-ascorbic acid eluting stent works as well as the standard everolimus-eluting stent for people with coronary artery disease undergoing PCI.

Quick facts

Study typeInterventional
Ages19 Years and up
SexAll
Enrollment2034 (estimated)
SponsorAsan Medical Center
Academic / other
Locations1 site (Seoul)
StatusRecruiting
StartedOctober 6, 2026
Main results expectedJune 15, 2027
Study endsJune 15, 2028
Registry record updatedOctober 7, 2026
Trial IDNCT07566091 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 19+ with chronic or acute coronary syndromes requiring PCI who can provide informed consent and tolerate dual antiplatelet therapy for 1 year.

Probably not a fit

Patients who have eligibility exclusions (e.g., recent cardiogenic shock, known drug hypersensitivities, inability to maintain DAPT, pregnancy) or who do not respond to treatment as intended may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In patients with chronic or acute coronary syndromes needing PCI, researchers compare the sirolimus-ascorbic acid eluting stent (D+Storm Novonix) to the widely used everolimus-eluting stent (Synergy XD) to see if it is not worse in preventing target lesion failure after one year. Target lesion failure combines cardiovascular death, target vessel heart attack, and need for revascularization at the treated site. The trial uses a noninferiority design to determine if the new stent provides comparable effectiveness and safety. Enrollment is open to adults 19 and older who can consent and meet the PCI criteria, with several safety exclusions in place.

Why it matters

Potential benefit: If successful, patients could have a new stent option that may offer similar protection with potential differences in safety or ease of use.

How similar studies have gone: Previous studies with sirolimus- or everolimus-eluting stents show benefit in PCI, but direct noninferiority data for sirolimus-ascorbic acid stents are needed.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Adult men and women aged 19 years or older
2. Patients with chronic coronary syndrome (CCS) or acute coronary syndrome (ACS) who require percutaneous coronary intervention (PCI) (all-comers)
3. Patients who have voluntarily provided written informed consent to participate in the study

Exclusion Criteria:

1. Cardiogenic shock within 48 hours prior to the procedure
2. Known hypersensitivity to sirolimus, everolimus, ascorbic acid, or stent components (e.g., cobalt-chromium alloy)
3. Patients unable to maintain dual antiplatelet therapy (DAPT), including aspirin and a P2Y12 inhibitor, for 1 year
4. Women who are pregnant, breastfeeding, or of childbearing potential who meet any of the following:

   * Have not confirmed a negative pregnancy test prior to enrollment
   * Do not agree to use, or are unlikely to maintain, an acceptable method of contraception during the study period
5. Clinically significant abnormalities identified during study visits, physical examination, laboratory tests, or electrocardiogram (ECG) that, in the investigator's judgment, may interfere with the safe completion of the study
6. Life expectancy of less than 1 year or presence of serious non-cardiac conditions that may affect compliance with the study protocol
7. Patients who are unwilling or unable to comply with the study protocol

Where it's running

  • Asan Medical Center
    Seoul, South Korea
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.